Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Gritstone Bio's GRANITE-001?
GRANITE-001 is a mrna vaccine commercialized by Gritstone Bio, with a leading Phase III program in Metastatic Colorectal Cancer. According...
GRANITE-001 by Gritstone Bio for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
GRANITE-001 is under clinical development by Gritstone Bio and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
GRANITE-001 by Gritstone Bio for Non-Small Cell Lung Cancer: Likelihood of Approval
GRANITE-001 is under clinical development by Gritstone Bio and currently in Phase II for Non-Small Cell Lung Cancer. According to...
GRANITE-001 by Gritstone Bio for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
GRANITE-001 is under clinical development by Gritstone Bio and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...
GRANITE-001 by Gritstone Bio for Metastatic Colorectal Cancer: Likelihood of Approval
GRANITE-001 is under clinical development by Gritstone Bio and currently in Phase III for Metastatic Colorectal Cancer. According to GlobalData,...
GRANITE-001 by Gritstone Bio for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
GRANITE-001 is under clinical development by Gritstone Bio and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....
Risk adjusted net present value: What is the current valuation of Gritstone Bio's GRANITE-001?
GRANITE-001 is a mrna vaccine commercialized by Gritstone Bio, with a leading Phase III program in Metastatic Colorectal Cancer. According...